SEARCH:   Advanced

Blood, 15 September 2007, Vol. 110, No. 6, pp. 2013-2019. Prepublished online as a Blood First Edition Paper on June 20, 2007; DOI 10.1182/blood-2006-12-061309. This Article Full Text Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2006-12-061309v1 110/6/2013    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chung, Y. Articles by Dong, C. Search for Related Content PubMed PubMed Citation Articles by Chung, Y. Articles by Dong, C. Related Collections Immunobiology Neoplasia Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY An NKT-mediated autologous vaccine generates CD4 T-cell–dependent potent antilymphoma immunity Yeonseok Chung1,3, Hong Qin2,3, Chang-Yuil Kang4, Sanghee Kim4, Larry W. Kwak2,3, and Chen Dong1,3 1 Department of Immunology and 2 Department of Lymphoma and Myeloma, 3 Center for Cancer Immunology Research, University of Texas M. D. Anderson Cancer Center, Houston, TX; 4 College of Pharmacy, Seoul National University, Seoul, Korea Relapses occurring in most patients with lymphoma after antibody or chemotherapy highlight a need for effective vaccination approaches. Autologous tumors are ideal sources of patient-specific tumor antigens for vaccines; however, their poor immunogenicity has been a major obstacle in practice. Natural killer T (NKT) cells have recently emerged as crucial regulators of autoimmunity and tumor immunosurveillance. Here, we show that an autologous lymphoma vaccine that activates NKT cells generated tumor-specific protective immunity in experimental mice. Single vaccination with -galactosylceramide (GC)-loaded A20 lymphoma cells elicited effective antitumor immunity against tumor challenge. This vaccination strategy also induced significant tumor regression in A20-bearing mice. Importantly, the survivors from primary tumor inoculation were all resistant to tumor rechallenge, indicative of established adaptive memory immunity. Depletion as well as adoptive transfer studies revealed an exclusive role of conventional CD4+ but not CD8+ T cells in mediating antitumor immunity. In addition, we found normal hematopoietic compartments in the vaccinated mice. Therefore, NKT ligand-loaded lymphoma elicits long-lasting and effective antitumor immunity, which can be further developed as patient- and tumor-specific immunotherapy against human lymphomas. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Hegde, E. Jankowska-Gan, D. A. Roenneburg, J. Torrealba, W. J. Burlingham, and J. E. Gumperz Human NKT cells promote monocyte differentiation into suppressive myeloid antigen-presenting cells J. Leukoc. Biol., October 1, 2009; 86(4): 757 - 768. [Abstract] [Full Text] [PDF] M. W. L. Teng, J. Sharkey, N. M. McLaughlin, M. A. Exley, and M. J. Smyth CD1d-Based Combination Therapy Eradicates Established Tumors in Mice J. Immunol., August 1, 2009; 183(3): 1911 - 1920. [Abstract] [Full Text] [PDF] C. Hong, H. Lee, Y.-K. Park, J. Shin, S. Jung, H. Kim, S. Hong, and S.-H. Park Regulation of Secondary Antigen-Specific CD8+ T-Cell Responses by Natural Killer T Cells Cancer Res., May 15, 2009; 69(10): 4301 - 4308. [Abstract] [Full Text] [PDF] E. Spanoudakis, M. Hu, K. Naresh, E. Terpos, V. Melo, A. Reid, I. Kotsianidis, S. Abdalla, A. Rahemtulla, and A. Karadimitris Regulation of multiple myeloma survival and progression by CD1d Blood, March 12, 2009; 113(11): 2498 - 2507. [Abstract] [Full Text] [PDF] H.-J. Ko, J.-M. Lee, Y.-J. Kim, Y.-S. Kim, K.-A Lee, and C.-Y. Kang Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine J. Immunol., February 15, 2009; 182(4): 1818 - 1828. [Abstract] [Full Text] [PDF] J. D. Brody, M. J. Goldstein, D. K. Czerwinski, and R. Levy Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors Blood, January 1, 2009; 113(1): 85 - 94. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020